Bristol Myers Squibb and Johnson & Johnson have stopped a phase 3 anticoagulant trial early for futility, closing off one avenue to market for a molecule tipped to generate multibillion-dollar sales.

Bristol Myers Squibb is expanding a partnership with oncology organization Sarah Cannon Research Institute, tapping into SCRI ...

The TV ad will run through Nov. 16 across major cable channels, including CNN, Fox News and ESPN, a BMS spokesperson told ...

BMS and J&J first linked together in 2018 to develop factor X1a inhibitors as anti-coagulants. The three Phase III Librexia ...

In an era where energy efficiency and sustainability are essential, BMS have emerged as critical components in industrial and ...

The IPO will comprise a public issue of 364.00 million new shares ("Issue Shares") and an offer for sale of 156.00 million existing shares ("Offer Shares"), collectively representing approximately ...